Stocks Fall as Oil Rises

Wall Street slips Tuesday as higher oil prices and rate worries weigh on sentiment ahead of key inflation data.

Market Snapshot

Get a Top Job Offer, Guaranteed (or tuition is free) | Apply Here

📉 Banana Bits

Market News

Stocks Slide as AI Fears and Rate Worries Hit Wall Street

Wall Street ended Tuesday lower as investors came back from the long weekend to several new concerns. The S&P 500 fell 0.6% to 7,673.52, the Dow dropped 628 points, or 1.2%, to 52,786.07, and the Nasdaq slipped 0.3% to 26,421.41. Software stocks were hit particularly hard as last week’s launch of OpenAI’s newest model, GPT-6 Astra, renewed concerns that AI could compete with services offered by traditional software companies. Salesforce and Intuit fell about 4%, while ServiceNow dropped 5%. Several chip stocks moved in the opposite direction, with Intel jumping 9% on reports of potential CPU price increases and Qualcomm gaining 3.2% after announcing an AI infrastructure deal with Amazon. The split suggested investors remain interested in AI, but are becoming more selective about which companies stand to benefit and which could face disruption.

Investors were also dealing with higher oil prices and interest rates. Brent crude briefly approached $100 a barrel on Tuesday after attacks on Saudi energy facilities increased concerns about global oil supply, while the 10-year Treasury yield hovered around 4.8%. Oil pressure continued into Wednesday morning, with Brent briefly exceeding $100 a barrel for the first time since July 23 before pulling back below that level.

Higher energy prices could make inflation harder to bring down, which matters because the Fed meets next week to decide whether to raise rates. Markets are currently pricing in about a 60% chance of a rate hike, making this week’s inflation reports especially important. Healthcare stocks also struggled, while energy companies benefited from the rise in crude prices. With inflation data coming later this week, investors are now waiting to see whether the Fed has another reason to keep rates higher.

Peel Take: Tuesday wasn’t a disaster, but the market suddenly has a lot to worry about at once. Oil is flirting with $100, rates are still high, and AI is starting to create clear winners and losers instead of lifting every tech company together. The interesting part is that chips held up while software got crushed, which tells you investors haven’t given up on AI they’re just getting more selective. Now inflation is the big test. A cooler report could calm rate-hike fears and give stocks some breathing room, while a hot one would make $100 oil and a possible Fed hike a much harder combination to ignore.

What's Ripe

Intel (INTC) 9.05% 

  • Intel jumped 9.05% to $104.47 after reports that the chipmaker plans to raise PC CPU prices by about 10% in October, following several earlier increases this year.

  • The reported pricing strategy is aimed at improving profitability amid strong product demand and higher component costs. Intel has not publicly confirmed the October increase.

  • Peel Take: Intel picked a good day to remind Wall Street that pricing power still exists. Raising prices while demand stays strong is exactly what investors want to see, especially when AI spending keeps supporting the chip industry. A 9% jump while the broader market was red makes the message pretty clear: investors still want exposure to the companies supplying the AI boom.

Qualcomm (QCOM) 3.17% 

  • Qualcomm gained 3.17% to $174.09 after announcing a multi-generation agreement with Amazon to develop customized AI data-center chips and advanced optical connectivity solutions.

  • The partnership could help Qualcomm grow beyond its traditional smartphone-chip business.

  • Peel Take: Qualcomm has spent years being known as the company inside your phone. Amazon just gave investors a reason to think bigger. If the company can become a serious AI data-center player, there could be a much larger growth story ahead.

What's Rotten

Amgen (AMGN) 10.08%

  • Amgen fell 10.08% after Novartis’ Phase 3 trial of pelacarsen failed to meet its primary endpoint of reducing cardiovascular events, despite lowering Lp(a) levels.

  • The result raised concerns about Amgen’s competing Lp(a)-lowering drug, olpasiran, which is being evaluated in its own Phase 3 cardiovascular outcomes trial.

  • Peel Take: Amgen didn't even fail its own trial and still lost 10%. That's how quickly biotech investors react when a competing drug runs into trouble. Now Amgen has to prove its treatment can deliver better results.

ServiceNow (NOW) 4.99%

  • ServiceNow fell 4.99% as OpenAI’s newest AI model renewed concerns that AI could compete with traditional enterprise software companies.

  • Other software stocks also fell as investors worried about AI disrupting their businesses.

  • Peel Take: AI used to lift almost every tech stock. Now investors are starting to ask which companies it could actually replace. ServiceNow still has opportunities to integrate AI into its platform, but investors increasingly want proof that those capabilities will strengthen its business rather than erode the value of its existing software.

🧠 Technical Trip

Interview Q&A from Moelis

👉 Want 1-on-1 recruiting help from Moelis bankers & 5,000+ top mentors? Apply to WSO Academy

🦈 Deal Dispatch

M&A, IPOs, And Other Notable Transactions

Student Success Corner

Banana Brain Teaser

Previous

A company has $150 million of revenue and $90 million of cost of goods sold. If inventory increases by $5 million and accounts payable increases by $3 million, what is the net change in working capital from these two items?

Answer: $2 million

Today

A company sells a product for $50 per unit, has variable costs of $30 per unit, and incurs $400,000 in fixed costs. How many units must it sell to break even?

“Be fearful when others are greedy and greedy when others are fearful.

Warren Buffett

How Would You Rate Today's Peel?


Happy Investing,
Chris, Elie, Mitchell, Fernanda, Nick, & Patrick